[go: up one dir, main page]

MX2025001924A - Precursores de fenetilaminas y catinonas - Google Patents

Precursores de fenetilaminas y catinonas

Info

Publication number
MX2025001924A
MX2025001924A MX2025001924A MX2025001924A MX2025001924A MX 2025001924 A MX2025001924 A MX 2025001924A MX 2025001924 A MX2025001924 A MX 2025001924A MX 2025001924 A MX2025001924 A MX 2025001924A MX 2025001924 A MX2025001924 A MX 2025001924A
Authority
MX
Mexico
Prior art keywords
cathinones
phenethylamines
parent
described technology
technology allows
Prior art date
Application number
MX2025001924A
Other languages
English (en)
Inventor
Bernard Cote
Jennifer Louise Schmidt
Martin Stogniew
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Publication of MX2025001924A publication Critical patent/MX2025001924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El tema de la invención se refiere en general a fenetilaminas o catinonas unidas covalentemente a una porción química en forma de profármaco. La tecnología descrita en la presente permite la administración lenta/sostenida/controlada de las fenetilaminas o catinonas originales en el sistema sanguíneo de una manera que aumenta la duración de la eficacia terapéutica, la facilidad de aplicación, el cumplimiento del paciente y/o una combinación de estas características cuando se administra, en particular, por vía oral. Además, la tecnología descrita permite la liberación gradual de las fenetilaminas o catinonas originales durante un período prolongado de tiempo, eliminando así los picos de los niveles del fármaco que reducen el estrés cardiovascular, el potencial de adicción/abuso y/u otros efectos secundarios estimulantes comunes asociados con los compuestos psicoactivos.
MX2025001924A 2022-08-17 2025-02-14 Precursores de fenetilaminas y catinonas MX2025001924A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263398703P 2022-08-17 2022-08-17
US202363471369P 2023-06-06 2023-06-06
PCT/US2023/030140 WO2024039599A1 (en) 2022-08-17 2023-08-14 Phenethylamines and cathinones precursors

Publications (1)

Publication Number Publication Date
MX2025001924A true MX2025001924A (es) 2025-07-01

Family

ID=89942178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001924A MX2025001924A (es) 2022-08-17 2025-02-14 Precursores de fenetilaminas y catinonas

Country Status (11)

Country Link
US (2) US12297220B2 (es)
EP (1) EP4573084A1 (es)
JP (1) JP2025527481A (es)
KR (1) KR20250107797A (es)
CN (1) CN120077032A (es)
AU (1) AU2023326364A1 (es)
CA (1) CA3264418A1 (es)
IL (1) IL318811A (es)
MX (1) MX2025001924A (es)
TW (1) TW202416951A (es)
WO (1) WO2024039599A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
PL132805B1 (en) 1981-08-26 1985-04-30 Ct Kt Maszyn Gorniczych Komag Turnout of underslung monorail
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
AU6104196A (en) * 1995-06-06 1996-12-24 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiopheno nes
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
BRPI0410792B8 (pt) * 2003-05-29 2021-05-25 New River Pharmaceuticals Inc compostos de anfetamina resistentes à dependencia
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
WO2010075520A1 (en) 2008-12-23 2010-07-01 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin enacarbil intermediate
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
TWI703147B (zh) 2015-11-24 2020-09-01 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療胃腸發炎性疾病之jak抑制劑化合物之前藥
PL232830B1 (pl) * 2017-02-23 2019-07-31 Dk Chem Organic Synthesis Ltd Spolka Komandytowa Nowe pochodne karbaminianów oraz ich zastosowanie
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
EP4211130A1 (en) * 2020-09-11 2023-07-19 COMPASS Pathfinder Limited Novel safrylamine derivatives having prodrug properties
WO2023137453A1 (en) * 2022-01-14 2023-07-20 Terran Biosciences Inc. Prodrugs of 3,4-methylenedioxy-n-methcathinone and uses thereof

Also Published As

Publication number Publication date
WO2024039599A9 (en) 2024-10-31
US20250129108A1 (en) 2025-04-24
EP4573084A1 (en) 2025-06-25
AU2023326364A1 (en) 2025-03-06
US12297220B2 (en) 2025-05-13
JP2025527481A (ja) 2025-08-22
IL318811A (en) 2025-04-01
KR20250107797A (ko) 2025-07-14
CN120077032A (zh) 2025-05-30
CA3264418A1 (en) 2024-02-22
WO2024039599A1 (en) 2024-02-22
TW202416951A (zh) 2024-05-01
US20250270242A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
JP2019131596A5 (es)
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
WO2004112711A3 (en) Oral extended-release composition
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
WO2005011769A3 (en) Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
DE602004019053D1 (de) Titrationsdosierschema für kontrolliert freigesetztes tramadol
WO2007036952A3 (en) Novel sustained release dosage form
UA106593C2 (uk) Пристрій для пролонгованого введення ліків, який містить полімери на основі поліуретану, та спосіб його виготовлення
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
CA2531833A1 (en) Poly-4-hydroxybutyrate matrices for sustained drug delivery
BR0013948A (pt) Prodroga, composição farmacêutica, e, método de tratamento de um paciente mamìfero
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
JP2014520893A5 (es)
AR060524A1 (es) Membranas asimetricas para dispositivos de administracion de farmacos
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
Ionescu et al. Current trends in identifying rapidly acting treatments for depression
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
MX2025001924A (es) Precursores de fenetilaminas y catinonas
Arantes et al. Tenoxicam controls pain without altering orthodontic movement of maxillary canines
Schenk et al. Serotonin antagonists fail to alter MDMA self-administration in rats